A Aralex Aachen research explorer

R. Veillon Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

0

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (2)

5× CHU Bordeaux, Service des Maladies Respiratoires, Bordeaux, France
1× CHU Bordeaux, service des maladies respiratoires, Bordeaux/FR

Papers 6 stored

All · Aachen affiliation only

P3.12.40 Safety and Patient-Reported Outcomes With Tepotinib in Patients With METex14 Skipping NSCLC: =3-Years Follow-Up of VISION
2025 Journal of Thoracic Oncology article Medicine Lung Cancer Treatments and Mutations Open access

2

citations
1995P Treatment (Tx) sequencing of tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Outcomes from ≥3 years follow-up of the VISION study
2025 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access

2

citations
1996P Long-term outcomes with tepotinib for clinically relevant subgroups of patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION study: A ≥3-year follow-up
2025 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access

0

citations
81P: Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes
2025 Journal of Thoracic Oncology article Medicine Lung Cancer Treatments and Mutations Open access

3

citations
34P Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
2023 Journal of Thoracic Oncology article Medicine Lung Cancer Treatments and Mutations Open access

1

citations
985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
2022 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access

1

citations

6 results